BioAge Labs, Inc. (NASDAQ:BIOA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

BioAge Labs, Inc. (NASDAQ:BIOA) has earned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $36.5714.

A number of equities analysts have weighed in on BIOA shares. Needham & Company LLC decreased their price objective on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research report on Friday, July 31st. BTIG Research reiterated a “buy” rating and issued a $40.00 price target on shares of BioAge Labs in a research note on Monday, August 3rd. Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Roth Capital restated a “buy” rating and set a $25.00 price objective on shares of BioAge Labs in a research note on Friday, July 31st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, July 21st.

BioAge Labs Stock Up 0.6%

BIOA opened at $10.46 on Wednesday. The firm’s 50 day moving average is $19.26 and its 200-day moving average is $18.74. BioAge Labs has a 52-week low of $4.38 and a 52-week high of $25.95. The firm has a market capitalization of $480.11 million, a P/E ratio of -4.39 and a beta of 0.94.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.07. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. The business had revenue of $2.45 million during the quarter. Equities analysts expect that BioAge Labs will post -2.45 earnings per share for the current fiscal year.

Institutional Trading of BioAge Labs

Several institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its stake in BioAge Labs by 60.8% during the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after acquiring an additional 171,426 shares during the last quarter. Walleye Capital LLC acquired a new stake in shares of BioAge Labs in the 2nd quarter valued at about $64,000. Marshall Wace LLP raised its stake in shares of BioAge Labs by 324.7% in the 2nd quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock valued at $937,000 after purchasing an additional 173,388 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of BioAge Labs by 85.6% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after purchasing an additional 5,976 shares during the last quarter. Finally, Ameriprise Financial Inc. bought a new position in shares of BioAge Labs during the second quarter worth about $182,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.